Discovery, synthesis, and biological evaluation of novel SMN protein modulators

Jingbo Xiao, Juan J. Marugan, Wei Zheng, Steve Titus, Noel Southall, Jonathan J. Cherry, Matthew Evans, Elliot Androphy, Christopher P. Austin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive disorder affecting the expression or function of survival motor neuron protein (SMN) due to the homozygous deletion or rare point mutations in the survival motor neuron gene 1 (SMN1). The human genome includes a second nearly identical gene called SMN2 that is retained in SMA. SMN2 transcripts undergo alternative splicing with reduced levels of SMN. Up-regulation of SMN2 expression, modification of its splicing, or inhibition of proteolysis of the truncated protein derived from SMN2 have been discussed as potential therapeutic strategies for SMA. In this manuscript, we detail the discovery of a series of arylpiperidines as novel modulators of SMN protein. Systematic hit-to-lead efforts significantly improved potency and efficacy of the series in the primary and orthogonal assays. Structure-property relationships including microsomal stability, cell permeability, and in vivo pharmacokinetics (PK) studies were also investigated. We anticipate that a lead candidate chosen from this series may serve as a useful probe for exploring the therapeutic benefits of SMN protein up-regulation in SMA animal models and a starting point for clinical development.

Original languageEnglish
Pages (from-to)6215-6233
Number of pages19
JournalJournal of Medicinal Chemistry
Volume54
Issue number18
DOIs
StatePublished - Sep 22 2011

Fingerprint

Motor Neurons
Spinal Muscular Atrophy
Proteins
Up-Regulation
Alternative Splicing
Human Genome
Point Mutation
Proteolysis
Genes
Permeability
Animal Models
Pharmacokinetics
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Xiao, J., Marugan, J. J., Zheng, W., Titus, S., Southall, N., Cherry, J. J., ... Austin, C. P. (2011). Discovery, synthesis, and biological evaluation of novel SMN protein modulators. Journal of Medicinal Chemistry, 54(18), 6215-6233. https://doi.org/10.1021/jm200497t

Discovery, synthesis, and biological evaluation of novel SMN protein modulators. / Xiao, Jingbo; Marugan, Juan J.; Zheng, Wei; Titus, Steve; Southall, Noel; Cherry, Jonathan J.; Evans, Matthew; Androphy, Elliot; Austin, Christopher P.

In: Journal of Medicinal Chemistry, Vol. 54, No. 18, 22.09.2011, p. 6215-6233.

Research output: Contribution to journalArticle

Xiao, J, Marugan, JJ, Zheng, W, Titus, S, Southall, N, Cherry, JJ, Evans, M, Androphy, E & Austin, CP 2011, 'Discovery, synthesis, and biological evaluation of novel SMN protein modulators', Journal of Medicinal Chemistry, vol. 54, no. 18, pp. 6215-6233. https://doi.org/10.1021/jm200497t
Xiao J, Marugan JJ, Zheng W, Titus S, Southall N, Cherry JJ et al. Discovery, synthesis, and biological evaluation of novel SMN protein modulators. Journal of Medicinal Chemistry. 2011 Sep 22;54(18):6215-6233. https://doi.org/10.1021/jm200497t
Xiao, Jingbo ; Marugan, Juan J. ; Zheng, Wei ; Titus, Steve ; Southall, Noel ; Cherry, Jonathan J. ; Evans, Matthew ; Androphy, Elliot ; Austin, Christopher P. / Discovery, synthesis, and biological evaluation of novel SMN protein modulators. In: Journal of Medicinal Chemistry. 2011 ; Vol. 54, No. 18. pp. 6215-6233.
@article{8c2ae8a4944a4e5bb0dfc637354f45b5,
title = "Discovery, synthesis, and biological evaluation of novel SMN protein modulators",
abstract = "Spinal muscular atrophy (SMA) is an autosomal recessive disorder affecting the expression or function of survival motor neuron protein (SMN) due to the homozygous deletion or rare point mutations in the survival motor neuron gene 1 (SMN1). The human genome includes a second nearly identical gene called SMN2 that is retained in SMA. SMN2 transcripts undergo alternative splicing with reduced levels of SMN. Up-regulation of SMN2 expression, modification of its splicing, or inhibition of proteolysis of the truncated protein derived from SMN2 have been discussed as potential therapeutic strategies for SMA. In this manuscript, we detail the discovery of a series of arylpiperidines as novel modulators of SMN protein. Systematic hit-to-lead efforts significantly improved potency and efficacy of the series in the primary and orthogonal assays. Structure-property relationships including microsomal stability, cell permeability, and in vivo pharmacokinetics (PK) studies were also investigated. We anticipate that a lead candidate chosen from this series may serve as a useful probe for exploring the therapeutic benefits of SMN protein up-regulation in SMA animal models and a starting point for clinical development.",
author = "Jingbo Xiao and Marugan, {Juan J.} and Wei Zheng and Steve Titus and Noel Southall and Cherry, {Jonathan J.} and Matthew Evans and Elliot Androphy and Austin, {Christopher P.}",
year = "2011",
month = "9",
day = "22",
doi = "10.1021/jm200497t",
language = "English",
volume = "54",
pages = "6215--6233",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "18",

}

TY - JOUR

T1 - Discovery, synthesis, and biological evaluation of novel SMN protein modulators

AU - Xiao, Jingbo

AU - Marugan, Juan J.

AU - Zheng, Wei

AU - Titus, Steve

AU - Southall, Noel

AU - Cherry, Jonathan J.

AU - Evans, Matthew

AU - Androphy, Elliot

AU - Austin, Christopher P.

PY - 2011/9/22

Y1 - 2011/9/22

N2 - Spinal muscular atrophy (SMA) is an autosomal recessive disorder affecting the expression or function of survival motor neuron protein (SMN) due to the homozygous deletion or rare point mutations in the survival motor neuron gene 1 (SMN1). The human genome includes a second nearly identical gene called SMN2 that is retained in SMA. SMN2 transcripts undergo alternative splicing with reduced levels of SMN. Up-regulation of SMN2 expression, modification of its splicing, or inhibition of proteolysis of the truncated protein derived from SMN2 have been discussed as potential therapeutic strategies for SMA. In this manuscript, we detail the discovery of a series of arylpiperidines as novel modulators of SMN protein. Systematic hit-to-lead efforts significantly improved potency and efficacy of the series in the primary and orthogonal assays. Structure-property relationships including microsomal stability, cell permeability, and in vivo pharmacokinetics (PK) studies were also investigated. We anticipate that a lead candidate chosen from this series may serve as a useful probe for exploring the therapeutic benefits of SMN protein up-regulation in SMA animal models and a starting point for clinical development.

AB - Spinal muscular atrophy (SMA) is an autosomal recessive disorder affecting the expression or function of survival motor neuron protein (SMN) due to the homozygous deletion or rare point mutations in the survival motor neuron gene 1 (SMN1). The human genome includes a second nearly identical gene called SMN2 that is retained in SMA. SMN2 transcripts undergo alternative splicing with reduced levels of SMN. Up-regulation of SMN2 expression, modification of its splicing, or inhibition of proteolysis of the truncated protein derived from SMN2 have been discussed as potential therapeutic strategies for SMA. In this manuscript, we detail the discovery of a series of arylpiperidines as novel modulators of SMN protein. Systematic hit-to-lead efforts significantly improved potency and efficacy of the series in the primary and orthogonal assays. Structure-property relationships including microsomal stability, cell permeability, and in vivo pharmacokinetics (PK) studies were also investigated. We anticipate that a lead candidate chosen from this series may serve as a useful probe for exploring the therapeutic benefits of SMN protein up-regulation in SMA animal models and a starting point for clinical development.

UR - http://www.scopus.com/inward/record.url?scp=80052814039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052814039&partnerID=8YFLogxK

U2 - 10.1021/jm200497t

DO - 10.1021/jm200497t

M3 - Article

VL - 54

SP - 6215

EP - 6233

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 18

ER -